Infectious Enteritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, Injectables), By Drug Type (Antibiotics, Antivirals, Others), By Region & Competition, 2021-2031F

The Global Infectious Enteritis Treatment Market is projected to expand significantly, rising from USD 512.21 Million in 2025 to USD 791.82 Million by 2031, reflecting a compound annual growth rate of 7.53%. This market sector includes pharmacotherapies like antibiotics and antivirals, as well as rehydration regimens designed to manage intestinal inflammation induced by pathogenic microorganisms. Growth is primarily underpinned by the increasing global incidence of diarrheal diseases and enhanced investment in healthcare infrastructure, which broadens access to vital medicines. For instance, the World Health Organization reported a 5% increase in global cholera cases in 2024 compared to the previous year, highlighting a persistent necessity for effective therapeutic interventions and ensuring sustained demand across affected regions.

A major obstacle hindering market progression is the rising prevalence of antimicrobial resistance among enteric pathogens. The spread of multidrug-resistant bacterial strains diminishes the efficacy of standard antibiotic treatments, resulting in complicated clinical outcomes and the need for intricate treatment protocols. This issue compels pharmaceutical developers to bear substantial costs in the pursuit of alternative therapies, establishing significant regulatory and economic barriers that limit market accessibility and growth.

Market Driver

The rising global prevalence of foodborne and waterborne enteric infections serves as a primary driver for market demand, as pathogens like Norovirus, Salmonella, and Listeria spread through complex supply chains and hygiene lapses. According to the United Kingdom Health Security Agency's 'National Norovirus and Rotavirus Report' from April 2024, laboratory reports of norovirus were 75% higher than the five-year average, underscoring the volatility of outbreaks and the urgent need for robust supply chains for rehydration salts and symptom-management drugs. Additionally, the Centers for Disease Control and Prevention noted a severe Listeria monocytogenes outbreak linked to deli meats in 2024 that caused 57 hospitalizations, reinforcing the critical necessity for potent antibiotic interventions and hospital-grade therapies.

Simultaneously, increased investment in research and development for novel antimicrobial and antiviral therapies is transforming the competitive landscape. To address the waning effectiveness of traditional antibiotics against resistant strains, both public and private sectors are directing capital toward next-generation treatments. For example, the United Kingdom Government announced an £85 million commitment in May 2024 specifically to support research into antimicrobial resistance and the development of new infectious disease treatments. This financial support helps pharmaceutical companies expedite clinical trials and navigate regulatory hurdles, ensuring a continuous pipeline of advanced therapeutic options to tackle evolving pathogenic threats.

Market Challenge

The growing prevalence of antimicrobial resistance poses a significant hurdle to the growth of the infectious enteritis treatment market. As enteric pathogens increasingly survive standard antibiotic regimens, the clinical value of existing pharmacotherapies declines, compelling pharmaceutical developers to invest heavily in discovering novel compounds. This transition requires complex, expensive research initiatives with high risks of failure, which reduces profit margins and deters new market entrants. Consequently, the financial strain of developing alternative therapies creates a restrictive economic climate that hampers the commercial scalability of treatment portfolios.

This challenge is reinforced by recent surveillance data highlighting the severity of the problem. In 2024, the European Centre for Disease Prevention and Control reported that 65.7% of Campylobacter coli isolates in humans across reporting countries were resistant to ciprofloxacin. Such high resistance rates hasten the obsolescence of frontline treatments, effectively shortening the viable lifespan of current inventories. As a result, the market contends with a continuous cycle of product devaluation, which obstructs long-term revenue growth and complicates the strategic planning necessary to maintain a steady supply of effective medicines.

Market Trends

The market is experiencing a significant shift toward microbiome-modulating therapeutics, particularly for managing recurrent Clostridioides difficile infections that frequently succeed standard antibiotic treatments. Unlike traditional antimicrobials that disturb gut ecology, these live biotherapeutic products are engineered to restore the intestinal microbial community, preventing pathogen recolonization and halting the cycle of recurrence. This trend is commercially supported by the success of the first FDA-approved oral microbiome therapy, VOWST; Seres Therapeutics reported in May 2024 that net sales for the drug reached $10.1 million in the first quarter, indicating rapid adoption by gastroenterologists seeking alternatives to standard care.

Concurrently, clinical management is being transformed by the adoption of rapid point-of-care molecular diagnostics, which replace slower culture methods with syndromic panel testing. These advanced platforms allow healthcare providers to detect a wide range of viral, bacterial, and parasitic pathogens from a single stool sample, drastically reducing diagnosis time and enabling targeted, narrow-spectrum treatment. The commercial success of these panels is evident in bioMerieux's September 2024 report, which noted that sales of BIOFIRE non-respiratory panels, including gastrointestinal solutions, grew organically by 19% in the first half of the year, supporting a more precise therapeutic approach and optimized patient isolation protocols.

Key Market Players

• Novartis AG
• Gilead Sciences Inc
• GlaxoSmithKline plc
• Janssen Global Services, LLC
• F. Hoffmann-La Roche Ltd.
• BioCryst Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH
• Sanofi A.G.
• Medtronic Plc.

Report Scope

In this report, the Global Infectious Enteritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Enteritis Treatment Market, By Route of Administration

• Oral
• Injectables

Infectious Enteritis Treatment Market, By Drug Type

• Antibiotics
• Antivirals
• Others

Infectious Enteritis Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infectious Enteritis Treatment Market.

Available Customizations:

Global Infectious Enteritis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).